Home/Filings/4/0000899243-22-001629
4//SEC Filing

Fryer Jeffrey M 4

Accession 0000899243-22-001629

CIK 0001739410other

Filed

Jan 10, 7:00 PM ET

Accepted

Jan 11, 8:03 PM ET

Size

34.7 KB

Accession

0000899243-22-001629

Insider Transaction Report

Form 4
Period: 2021-07-28
Fryer Jeffrey M
See Remarks
Transactions
  • Other

    Common Units

    2021-07-281,282,5000 total(indirect: See footnote)
    Common Stock (190,156 underlying)
  • Other

    Series A-1 Preferred Units

    2021-07-2875,0000 total(indirect: See footnote)
    Common Stock (11,778 underlying)
  • Other

    Series A-2 Preferred Units

    2021-07-28100,0000 total(indirect: See footnote)
    Common Stock (15,704 underlying)
  • Other

    Common Stock

    2021-07-28+272,609272,609 total(indirect: See Footnote)
  • Other

    Common Stock

    2021-07-28+201,934201,934 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2022-01-07$8.97/sh+705$6,32433,353 total(indirect: See Footnote)
  • Other

    Common Units

    2021-07-282,255,0000 total(indirect: See footnote)
    Common Stock (272,609 underlying)
  • Other

    Series A-1 Preferred Units

    2021-07-2875,0000 total(indirect: See footnote)
    Common Stock (11,778 underlying)
  • Other

    Series B Preferred Units

    2021-07-28107,8910 total(indirect: See footnote)
    Common Stock (16,944 underlying)
  • Other

    Common Stock

    2021-07-28+32,64832,648 total(indirect: See Footnote)
  • Other

    Common Stock

    2021-07-28+201,934201,934 total(indirect: See Footnote)
  • Purchase

    Common Stock

    2022-01-07$9.44/sh+9,295$87,74542,648 total(indirect: See Footnote)
  • Other

    Common Units

    2021-07-281,282,5000 total(indirect: See footnote)
    Common Stock (190,156 underlying)
  • Award

    Option (Right to Buy)

    2021-07-28+160,000160,000 total
    Exercise: $13.00Exp: 2031-07-28Common Stock (160,000 underlying)
Footnotes (8)
  • [F1]The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation.
  • [F2]Shares of common stock are held in a Roth IRA.
  • [F3]Shares of common stock are held in a revocable trust for which Mr. Fryer is the grantor.
  • [F4]Shares of common stock are held in an irrevocable trust for the benefit of one of Mr. Fryer's children. Mr. Fryer disclaims beneficial ownership of such shares.
  • [F5]Shares of common stock are held in an irrevocable trust for the benefit of one of Mr. Fryer's children. Mr. Fryer disclaims beneficial ownership of such shares.
  • [F6]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.01 to $9.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.
  • [F7]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $10.00, inclusive.
  • [F8]The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter.

Issuer

Rallybio Corp

CIK 0001739410

Entity typeother

Related Parties

1
  • filerCIK 0001872879

Filing Metadata

Form type
4
Filed
Jan 10, 7:00 PM ET
Accepted
Jan 11, 8:03 PM ET
Size
34.7 KB